Meeting
2016 Genitourinary Cancers Symposium
Detection of prostate cancer with the [68Ga]-labeled bombesin antagonist RM2 in patients undergoing radical prostatectomy.
Authors
Andrew Stephens
Piramal Imaging, Berlin, Germany
Andrew Stephens , Wolfgang C. Loidl , Mohsen Beheshti , Ivan Jambor , Jukka Kemppainen , Peter Bostrom , Esa Kahkonen , Mathias Berndt , Andre Mueller , Heikki Minn , Werner Langsteger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Localized Disease
Clinical Trial Registration Number
NCT02483884
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 80)
DOI
10.1200/jco.2016.34.2_suppl.80
Abstract #
80
Poster Bd #
D18
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
PSMA PET findings in an “EMBARK-like” cohort of patients with high-risk non-metastatic hormone-sensitive prostate cancer: A single center post-hoc retrospective analysis.
First Author: Wesley Robert Armstrong
Poster
2023 ASCO Genitourinary Cancers Symposium
Length and Gleason pattern at positive surgical margin after radical prostatectomy to assess risk of postoperative recurrence in localized prostate cancer.
First Author: Masashi Kato
Poster
2020 Genitourinary Cancers Symposium
Prospective comparison of 68Ga-RM2 PET/CT and 68Ga-PSMA-617 PET/CT for initial staging of prostate cancer.
First Author: Romain Schollhammer Sr.
Poster
2015 Genitourinary Cancers Symposium
Are patients with Gleason 6 pathology safe from developing metastatic castration-resistant prostate cancer (mCRPC)?
First Author: Christoph A. J. von Klot